Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronickidneydisease CKD-EPI ChronicKidneyDisease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice ESKD End-stage kidneydisease HD Hemodialysis HR Hazard ratio KFRE Kidney Failure Risk Equation MD Mean Difference MDRD Modification of Diet in RenalDisease OR Odds Ratio (...) PD Peritoneal dialysis QoL Quality of life RCT Randomized controlled trial REIN Renal Epidemiology and Information Network RR Relative Risk RRT Renal replacement therapy SGA Subjective global assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronickidneydisease CKD-EPI ChronicKidneyDisease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP
and effective assessment of the patient's condition • Optimize the use of therapy to reduce disease progression, reduce symptoms of CKD, and enhance patient functionality • Minimize preventable complications and morbidity • Emphasize the use of personalized, proactive, patient-driven care December 2014 Page 5 of 117 Background Chronickidneydisease is one of the most common serious medical conditions affecting adults in the United States (US). The Centers for Disease Control and Prevention (CDC) estimate (...) to display each step in the algorithm, and arrows connect the numbered boxes indicating the order in which the steps should be followed.  Rounded rectangles represent a clinical state or condition. Hexagons represent a decision point in the guideline, formulated as a question that can be answered Yes or No. Rectangles represent an action in the process of care. December 2014 Page 12 of 117 December 2014 Page 13 of 117 Recommendations # Recommendation Strength Evaluation for ChronicKidneyDisease
KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronickidneydisease&mdash KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronickidneydisease—mineral and bone disorder (CKD-MBD). | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused (...) , read our . Guideline Summary NGC:011233 2017 Jul NEATS Assessment KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronickidneydisease—mineral and bone disorder (CKD-MBD). KidneyDisease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronickidneydisease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of ChronicKidneyDisease-Mineral and Bone Disorder (CKD-MBD) KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of ChronicKidneyDisease–Mineral and Bone Disorder (CKD-MBD) - American Journal of KidneyDiseases Email/Username: Password: Remember me Search Terms Search within Search Share (...) this page Access provided by Volume 70, Issue 6, Pages 737–751 KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of ChronicKidneyDisease–Mineral and Bone Disorder (CKD-MBD) x Tamara Isakova Affiliations Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
combinations. 4. In most cases, combination therapy with other antihypertensive agents might be needed to reach target BP levels (Grade D). This recommendation is based on expert consensus. 5. The combination of an ACE inhibitor and ARB is not recommended for patients with nonproteinuric chronickidneydisease (Grade B). Dual renin-angiotensin system (RAS) inhibition has been shown to reduce significantly proteinuria , a surrogate endpoint for cardiovascular disease, and renal impairment in patients (...) to develop future recommendations for these patient populations. References Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood- pressure control on the progression of chronicrenaldisease. Modification of Diet in RenalDisease Study Group. N Engl J Med 1994;330:877-84. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidneydisease: long-term follow-up of the Modification of Diet in RenalDisease study. Ann Intern
using some of the common high-protein (HP) weight-loss diets. The American Recommended Daily Allowance (RDA) for protein is approximately 0.8g/kg/d. Typically, Americans consume approximately 1.2g/kg/d or 15% total energy. The author defined HP diet was > 1.5g/kg/d or > 25% total energy. The literature reported that HP consumption has been found, under various conditions, to lead to glomerular hyperfiltration and hyperaemia, acceleration of chronickidneydisease (CKD), increased proteinuria (...) . This study was potentially limited by indication bias with residual confounding, recall bias and ascertainment bias (18.6% of Medical Evidence Report Forms were missing). Campbell et al  reported the results of a retrospective evaluation of the impact of initiating specific nutrition care guidelines for haemodialysis patients, as described in the Evidence-Based Practice Guidelines for the Nutritional Management of ChronicKidneyDisease , by renal dietitians every 6 months at a public tertiary
Interventions for improving sleep quality in people with chronickidneydisease. Sleep disorders are commonly experienced by people with chronickidneydisease (CKD). Several approaches for improving sleep quality are used in clinical practice including relaxation techniques, exercise, acupressure, and medication.To assess the effectiveness and associated adverse events of interventions designed to improve sleep quality among adults and children with CKD including people with end-stage kidney (...) disease (ESKD) treated with dialysis or kidney transplantation.We searched the Cochrane Kidney and Transplant Register of Studies up to 8 October 2018 with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials (RCTs) or quasi-randomised RCTs
energy wasting syndrome in chronickidneydisease: a consensus statement from the International Society of Renal Nutrition and Metabolism. Journal of Renal Nutrition 2013; 23: 77-90. 24. Koo JR, Park KY, Kim HJ, Che DW, Lee JS, Son BW, Rho JW. Depression in chronic haemodialysis patients: risk factors and effects on nutritional parameters. Journal of the American Society of Nephrology 1998; 9: 216A 25. Kopple JD, Greene T, Chumlea WC, Hollinger D, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang SR (...) Undernutrition in ChronicKidneyDisease Clinical Practice Guideline Undernutrition in ChronicKidneyDisease Authors: Dr Mark Wright Consultant Nephrologist, St J am es ’s University Hospital, Leeds Mrs Elizabeth Southcott Senior Specialist Renal Dietitian, St J a m es’s University Hospital, Leeds Dr Helen MacLaughlin, Consultant Dietitian, Kings College Hospital Mr Stuart Wineberg Patient Representative Final Version: June 2019 Review Date: June 2024 2 Endorsements The National Institute
kidney injury (AKI). A small, but significant, number of cases progress to end-stage renaldisease (ESRD) requiring dialysis or kidney transplant, which carries a major personal, social, and economic burden. Historically, CKD was considered to be a condition to be managed primarily by specialists. However, the introduction of laboratory reporting of the estimated glomerular filtration rate (eGFR) alongside serum creatinine values has improved the identification of people with CKD in primary care (...) to be considered when dosing patients with renal impairment? Medicines Q&A 167.6. February 2016. https://www.sps.nhs.uk/articles/what-factors-need-to-be-considered-when- dosing-patients-with-renal-impairment-2/. Accessed 2 May 2017. 9. Webster AC et al. ChronicKidneyDisease. Lancet 2016; 389(10075): 1238-1252. 10. Anonymous. Sick day rules in kidneydisease. Drug and Therapeutics Bulletin April 2015; 53(4) 11. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection
Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronickidneydisease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs
with diabetes mellitus and/or hypertension should be screened at least yearly for chronickidneydisease (CKD). • Screening for CKD may be considered for patients with: ? age >65 years old ? obesity ? cardiovascular disease ? metabolic syndrome ? drugs e.g. nephrotoxic drugs, long-term use of proton-pump inhibitors or analgesics ? family history of CKD or hereditary kidneydisease ? gout ? multisystem diseases with potential kidney involvement e.g. systemic lupus erythematosus ? structural renal tract (...) Reviewers x Algorithm 1 Screening and Investigations for xi ChronicKidneyDisease in Adults with Diabetes Algorithm 2 Screening and Investigations for xii ChronicKidneyDisease in Adults without Diabetes Algorithm 3 Evaluation of Haematuria in xiii ChronicKidneyDisease in Adults Algorithm 4 Treatment for ChronicKidneyDisease xiv in Adults 1. INTRODUCTION 1 2. RISK FACTORS 2 3 ASSESSMENT 4 3.1 Screening 4 3.2 Renal Function 6 3.3 Renal Ultrasound 7 3.4 Classification 8 4. INTERVENTIONS IN DELAYING
with a hospital referral 21 Patient involvement in CKD 21 Appendices Appendix 1 - Where can I get more information? 22 Appendix 2 - Contact Details 23 Appendix 3 - Management of chronickidneydisease: summary table 24 Appendix 4 - Abbreviations 25 Appendix 5 - Membership of GDG 26 3 Introduction Chronickidneydisease (CKD) is common, usually unrecognised and often exists in association with other conditions such as diabetes and cardiovascular disease. CKD is a general term covering a number of primary (...) risk of cardiovascular events, acute kidney injury, falls, frailty and mortality. Table 1: Prevalence of ChronicKidneyDisease Stage Description eGFR (mL/min/1.73m 2 ) Population Prevalence 1 CKD with normal GFR + other kidney damage >90 3.3% 2 Mild CKD and other kidney damage 60-89 3.0% 3a 3b Mild to Moderate CKD Moderate to Severe CKD 45-59 30-44 4.3% 4 Severe CKD 15-29 0.2% 5 Established renal failure 30mg/mmol (macro-albuminuria often dipstick proteinuria) ? GFR in healthy young adults
. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine. 2004; 351: 1285-1295. 4. Brantsma AH, Bakker SJL, Hillege HL et al. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronickidneydisease: the importance of urinary albumin excretion. Nephrology Dialysis Transplantation. 2008; 23: 3851-8. 5. Chien K-L, Hsu H-C, Lee Y-T et al. Renal function and metabolic syndrome (...) ) and guidelines (Diabetes Australia) should incorporate these recommendations. Audits of primary health care providers should be commissioned to evaluate awareness of these guidelines and to monitor relevant key performance indicators, including blood pressure targets, and cardiovascular and renal outcomes. ____________________________________________________________________________________________________________ Early ChronicKidneyDisease July 2012 Page 2 of 24 BACKGROUND Chronickidneydisease (CKD
and Evaluation BM Bone marrow CBC Complete blood count CERA Continuous erythropoietin receptor activator CHOIR CorrectionofHemoglobin andOutcomesin Renal Insuf?ciency CI Con?dence interval CKD Chronickidneydisease CKiD ChronicKidneyDisease in Children Prospective Cohort Study COGS Conference on Guideline Standardization CREATE Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta Trial CRP C-reactive protein CVD Cardiovascular disease eGFR Estimated glomerular ?ltration rate EMA (...) KDIGO Clinical Practice Guideline for Anemia in ChronicKidneyDisease VOLUME 2 | ISSUE 4 | AUGUST ?2? 2012 http://www.kidney-international.org OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF NEPHROLOGY KDIGO Clinical Practice Guideline for Anemia in ChronicKidneyDisease KI_SuppCover_2.4.indd 1 KI_SuppCover_2.4.indd 1 7/11/12 12:00 PM 7/11/12 12:00 PMKDIGO Clinical Practice Guideline for Anemia in ChronicKidneyDisease KDIGO gratefully acknowledges the following consortium of sponsors